MeMed is a host response, med-tech & bioconvergence company, offering innovative diagnostic host response tests that address complex clinical dilemmas & improve patient outcomes.
Location: Israel, Haifa District, Haifa
Total raised: $176.2M
Investors 3
| Date | Name | Website |
| - | Western Te... | westerntec... |
| 03.08.2023 | Shavit Cap... | shavitcapi... |
| - | Social Cap... | socialcapi... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 20.09.2018 | - | $70M | - |
| 07.02.2018 | - | $4M | - |
| 26.04.2017 | - | $9.2M | - |
| - | - | $93M | - |
Mentions in press and media 19
| Date | Title | Description |
| 24.07.2025 | MeMed Completes Development of First-Ever Fingerstick Host-Response Test for Rapid Differentiation of Bacterial and Viral Infections | -MeMed BV Flex™ simultaneously measures multiple host proteins, paired with machine learning, to deliver highly accurate results in 15 minutes from just a few drops of blood- -Designed for use in decentralized, CLIA-waived settings, the tes... |
| 05.06.2025 | MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics | – Milestone Achieved Through Growing Clinical Evidence Demonstrating Real-World Impact on Infection Management – – MeMed and Physicians Premier Celebrated Milestone Event in Corpus Christi, Texas – ANDOVER, Mass. & HAIFA, Israel–(BUSINE... |
| 27.02.2025 | MeMed BV Proven to Optimize Antibiotic Use, Outperform Standard Care, and Cut Costs in New Studies | – Three New Peer-Reviewed Studies Confirm MeMed BV’s Clinical and Economic Value Across Urgent Care, Emergency Settings, and Hospitals – ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)–February 27, 2025– MeMed, a leader in host-response ... |
| 09.01.2025 | MeMed Expands Advisory Board with Key Leaders to Advance Host-Response Diagnostics for Sepsis and AMR | – Renowned Experts Beat Müller, Dave Hickey, and David Shulkin Join MeMed’s Advisory Board – ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)–January 9, 2025– MeMed, a leader in host-response diagnostics, today announced the addition of t... |
| 13.12.2024 | The Future of Medicine: Breakthroughs in Diagnostics and Gene Therapy | In the ever-evolving landscape of healthcare, two recent developments stand out like beacons of hope. The FDA's Breakthrough Device Designation for MeMed Severity and Cimeio Therapeutics' $300 million partnership with Kyowa Kirin mark signi... |
| 10.12.2024 | FDA Grants Breakthrough Device Designation to MeMed Severity Test for Patients with Suspected Sepsis | -Major Development Milestone Reinforces MeMed’s Leadership in Host-Response Diagnostics- -FDA Endorsement Accelerates Product Development and Market Readiness- ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)–December 10, 2024– MeMed, a l... |
| 07.12.2021 | Lighting Up The World: The Game-Changing Technologies That Will Set New Standards In 2022 | Nine prominent Israeli tech companies presented their world-changing technologies to UN ambassadors |
| 02.06.2020 | OurCrowd launches $100M Pandemic Innovation Fund to invest in tech startups that target solutions for COVID 19 and future pandemics | OurCrowd, a Jerusalem, Israel-based venture capital firm and the world’s largest crowdfunded-venture investment platform, today announced the launch of $100 million Pandemic Innovation Fund for investment in urgent technological solutions f... |
| 13.02.2020 | Interested in Investing in Early Stage Firms? OurCrowd Has a Long List, Reports 36 Exits to Date | OurCrowd is arguably the leading investment crowdfunding platform in the world. Based in Israel but listing offerings from companies around the world, OurCrowd has seen approximately $1.4 billion in committed funding since inception. Of the... |
| 07.03.2019 | Global Investment Platform OurCrowd Tops $1 Billion Raised, Reports 29 Exits | OurCrowd, the largest investment crowdfunding platform in the world, has topped $1 billion in funding raised. The online investment platform has provided growth capital to 170 individual firms and 18 different funds in the six years since t... |
Show more